Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  toremifene
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-17 of 17 for your search:
Start Over
Phase III Efficacy and Safety Trial of Toremifene vs Tamoxifen in Postmenopausal/Perimenopausal Patients with Metastatic Breast Cancer (Summary Last Modified 08/90)
Phase: Phase III
Type: Treatment
Status: Closed
Age: peri/postmenopausal
Sponsor:
Protocol IDs: GUMC-9989, NCI-V89-0180
Phase III Efficacy and Safety Trial of Toremifene vs Tamoxifen in Postmenopausal/Perimenopausal Patients with Metastatic Breast Cancer (Summary Last Modified 11/91)
Phase: Phase III
Type: Treatment
Status: Closed
Age: post/perimenopausal
Sponsor:
Protocol IDs: AECM-8805150, NCI-V89-0202
Phase III Efficacy and Safety Trial of Toremifene vs Tamoxifen in Postmenopausal/Perimenopausal Patients with Metastatic Breast Cancer (Summary Last Modified 01/90)
Phase: Phase III
Type: Treatment
Status: Closed
Age: post/perimenopausal
Sponsor:
Protocol IDs: TCSC-092006-999, NCI-V89-0043
Phase III Trial of the Efficacy and Safety of Toremifene vs Tamoxifen in Postmenopausal and Perimenopausal Patients with Metastatic Breast Cancer (Summary Last Modified 05/90)
Phase: Phase III
Type: Treatment
Status: Completed
Age: postmenopausal
Sponsor:
Protocol IDs: YALE-HIC-5026, NCI-V89-0229
Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: under 71
Sponsor: Other
Protocol IDs: CDR0000078385, IBCSG-12-93, EU-93015, NCI-F93-0010, NCT00002529
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Biomed 777-CLP-29, NCT00044291
Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
Phase: Phase III
Type: Prevention
Status: Completed
Age: 30 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: G300104, NCT00106691
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 50 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: G300203, NCT00129142
Phase II Randomized Study of Interferon Alfa with or without Toremifene for Completely Resected Stage II or III Melanoma (Summary Last Modified 08/1999)
Phase: Phase II
Type: Treatment
Status: Closed
Age: guardian's consent or over 18
Sponsor: Other
Protocol IDs: UCHSC-COMIRB-96044, NCI-V96-0827
Phase II Study of Toremifene plus Cisplatin in Metastatic non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CHNMC-IRB-95061, LAC-USC-94A041-CC, UCD-95143, NCI-V96-1032
Toremifene in Treating Patients With Ovarian Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000067029, GWCC-7096, NCI-V99-1540, NCT00003865
Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: PCI-00-105, CDR0000068708, PCI-N01-CN-75018, NCI-P01-0181, NCT00020735
Phase II Study of Toremifene in Patients with Inoperable Stage III/IV Malignant Melanoma (Summary Last Modified 02/90)
Phase: Phase II
Type: Treatment
Status: Closed
Age: any age
Sponsor:
Protocol IDs: EORTC-18891
Phase II Study of Toremifene in Peri- and Postmenopausal Patients with Advanced Breast Cancer Refractory to Tamoxifen (Summary Last Modified 01/90)
Phase: Phase II
Type: Treatment
Status: Closed
Age: peri/postmenopausal
Sponsor:
Protocol IDs: YALE-HIC-5138, NCI-V89-0231
A Phase II Study of Toremifene in Patients with Metastatic ER-Negative and PgR-Negative Breast Cancer (Summary Last Modified 07/91)
Phase: Phase II
Type: Treatment
Status: Closed
Age: post/perimenopausal
Sponsor: NCI
Protocol IDs: CLB-8945, CALGB-8945
Start Over